Davis Sam1, Gregory A Kline1, Benny So2, Janice L Pasieka3, Adrian Harvey3, Alex Chin4,5, Stefan J Przybojewski2, Alexander A Leung1,6. 1. Department of Medicine, University of Calgary, Calgary, Alberta, Canada. 2. Department of Radiology, University of Calgary, Calgary, Alberta, Canada. 3. Department of Surgery, University of Calgary, Calgary, Alberta, Canada. 4. Alberta Precision Laboratories, Alberta Health Services, Calgary, Alberta, Canada. 5. Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada. 6. Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Abstract
CONTEXT: Many patients with unilateral primary aldosteronism (PA) have normal adrenal imaging, but little is known about their outcome following adrenalectomy. OBJECTIVE: To evaluate biochemical and clinical outcomes after adrenalectomy in patients with unilateral PA and normal-appearing adrenal imaging. DESIGN: Retrospective cohort study of patients seen between January 2006 and May 2018. SETTING: A Canadian tertiary care PA referral center. PATIENTS: Consecutive individuals with PA, normal cross-sectional adrenal imaging, and lateralizing adrenal vein sampling (AVS) who underwent adrenalectomy during the study period. PRIMARY OUTCOME: Biochemical response to adrenalectomy graded according to the Primary Aldosteronism Surgical Outcome criteria. RESULTS: A total of 40 patients were included. Biochemical outcomes were available for 33 people (mean age, 54.7 years; 91% male; median follow-up, 2.7 months), with 28 (85%) showing a complete or partial response and 5 (15%) with no response. Clinical outcomes were available for 36 people (mean age, 54.6 years; 86% male; median follow-up, 9.8 months), with 31 (86%) demonstrating a complete or partial response and 5 (14%) with no response. CONCLUSIONS: The prognosis after adrenalectomy is highly favorable for patients with unilateral PA and normal-appearing adrenal imaging. Patients with lateralizing disease should be considered for surgery despite apparently normal adrenal imaging.
CONTEXT: Many patients with unilateral primary aldosteronism (PA) have normal adrenal imaging, but little is known about their outcome following adrenalectomy. OBJECTIVE: To evaluate biochemical and clinical outcomes after adrenalectomy in patients with unilateral PA and normal-appearing adrenal imaging. DESIGN: Retrospective cohort study of patients seen between January 2006 and May 2018. SETTING: A Canadian tertiary care PA referral center. PATIENTS: Consecutive individuals with PA, normal cross-sectional adrenal imaging, and lateralizing adrenal vein sampling (AVS) who underwent adrenalectomy during the study period. PRIMARY OUTCOME: Biochemical response to adrenalectomy graded according to the Primary Aldosteronism Surgical Outcome criteria. RESULTS: A total of 40 patients were included. Biochemical outcomes were available for 33 people (mean age, 54.7 years; 91% male; median follow-up, 2.7 months), with 28 (85%) showing a complete or partial response and 5 (15%) with no response. Clinical outcomes were available for 36 people (mean age, 54.6 years; 86% male; median follow-up, 9.8 months), with 31 (86%) demonstrating a complete or partial response and 5 (14%) with no response. CONCLUSIONS: The prognosis after adrenalectomy is highly favorable for patients with unilateral PA and normal-appearing adrenal imaging. Patients with lateralizing disease should be considered for surgery despite apparently normal adrenal imaging.
Authors: Gian Paolo Rossi; Marlena Barisa; Bruno Allolio; Richard J Auchus; Laurence Amar; Debbie Cohen; Christoph Degenhart; Jaap Deinum; Evelyn Fischer; Richard Gordon; Ralph Kickuth; Gregory Kline; Andre Lacroix; Steven Magill; Diego Miotto; Mitsuhide Naruse; Tetsuo Nishikawa; Masao Omura; Eduardo Pimenta; Pierre-François Plouin; Marcus Quinkler; Martin Reincke; Ermanno Rossi; Lars Christian Rump; Fumitoshi Satoh; Leo Schultze Kool; Teresa Maria Seccia; Michael Stowasser; Akiyo Tanabe; Scott Trerotola; Oliver Vonend; Jiri Widimsky; Kwan-Dun Wu; Vin-Cent Wu; Achille Cesare Pessina Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: Gian Paolo Rossi; Valeria Bisogni; Alessandra Violet Bacca; Anna Belfiore; Maurizio Cesari; Antonio Concistrè; Rita Del Pinto; Bruno Fabris; Francesco Fallo; Cristiano Fava; Claudio Ferri; Gilberta Giacchetti; Guido Grassi; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Giuseppe Maiolino; Dario Manfellotto; Pietro Minuz; Silvia Monticone; Alberto Morganti; Maria Lorenza Muiesan; Paolo Mulatero; Aurelio Negro; Gianfranco Parati; Martino F Pengo; Luigi Petramala; Francesca Pizzolo; Damiano Rizzoni; Giacomo Rossitto; Franco Veglio; Teresa Maria Seccia Journal: Int J Cardiol Hypertens Date: 2020-04-15
Authors: Gregory A Kline; Janice L Pasieka; Adrian Harvey; Benny So; Val C Dias Journal: J Clin Hypertens (Greenwich) Date: 2014-05-27 Impact factor: 3.738